TRAX
Live chart
What they do
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues.
For information only · Important disclosures
Grades vs sector
No sector grades for TRAX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | -0.80 | -0.95 | -18.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-06-30 | $0 | – |
| 2025-03-31 | $0 | – |
Analyst actions
PT $90
PT $60
PT $70
PT $70
PT $50
PT $65
Insider trades
$1.8M
–
–
–
–
–
–
–
Stats refreshed 2026-10-21 12:15:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026